Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro.
Aminoguanidine (AG) has been proposed as a drug of potential benefit in prophylaxis of the complications of diabetes. We show here that AG irreversibly inhibits catalase with an efficacy similar to aminotriazole. AG also produces hydrogen peroxide, in a transition metal-catalysed process which may be partially dependent upon prior hydrolysis of AG to semicarbazide and hydrazine. These observations may be of importance in proposals for the long term administration of AG in diabetes.
Ou
P
P
Department of Medicine, University College London Medical School, Rayne Institute, U.K.
Wolff
S P
SP
D000640:Amitrole / Q000633:toxicity; D000818:Animals; D002374:Catalase / Q000037:antagonists & inhibitors*; D003300:Copper; D003920:Diabetes Mellitus / Q000201:enzymology; D004912:Erythrocytes / Q000187:drug effects / Q000201:enzymology; D006146:Guanidines / Q000494:pharmacology* / Q000633:toxicity; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012663:Semicarbazides / Q000494:pharmacology
D006146:Guanidines; D012663:Semicarbazides; C010059:carbamylhydrazine; D003300:Copper; D006861:Hydrogen Peroxide; D002374:Catalase; C004479:pimagedine; D000640:Amitrole